Stem cells and cancer cells have enough molecular similarities that the former can be used to trigger immunity against the latter.
The Scientist is bringing together a panel of experts to weigh in on the progress that immunotherapy has made.
July 19, 2017|
Immunotherapy has been hailed as a breakthrough for treating the untreatable, but it has not yet lived up to its promise to eradicate cancer and infectious disease. While there have been a number of exciting advances, there are still several real-world hurdles for immunotherapy to surmount before it becomes a standard option for most patients. The Scientist is bringing together a panel of experts to weigh in on the progress that immunotherapy has made, particularly in the search for effective anticancer treatments, and to discuss the steps still needed before immunotherapy becomes standard treatment in the clinic. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.
Topics to be covered:
Jill O’Donnell-Tormey, PhD
CEO and Director of Scientific Affairs
Cancer Research Institute
Alex Y. Huang, MD, PhD
Professor, Departments of Pediatrics,
Pathology, Biomedical Engineering,
and General Medical Sciences,
Case Western Reserve University School of Medicine,
UH Rainbow Babies & Children's Hospital